Wat is de plaats van raloxifene bij de behandeling van osteoporose

@inproceedings{Voort2006WatID,
  title={Wat is de plaats van raloxifene bij de behandeling van osteoporose},
  author={D. V. D. Voort},
  year={2006}
}
Raloxifene (Evista®) is een SERM (selective estrogen receptor modulator). Het is geen hormoon, maar bootst het effect na van oestrogeen in onder andere het bot en borstweefsel. De stof neemt (voor een deel) de plaats in van oestrogeen op de oestrogeenreceptor en heeft daarmee invloed op het proces ’oestrogeen > oestrogeen-receptor > receptor response > eindproduct’. 

References

SHOWING 1-6 OF 6 REFERENCES
Raloxifene: a review of its use in postmenopausal osteoporosis.
TLDR
The lack of stimulatory effects on the endometrium and the reduction in invasive breast cancer incidence indicate raloxifene as an attractive alternative to HRT for the management of postmenopausal osteonorosis. Expand
Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis.
TLDR
The effects of treatments on the risk of vertebral and nonvertebral fractures and on bone density, including effects in different patient subgroups are summarized and an estimate of the expected impact of antiosteoporosis interventions in prevention and treatment populations is provided using the number needed to treat (NNT) as a reference. Expand
Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial
TLDR
Raloxifene therapy for 4 years did not significantly affect the risk of cardiovascular events in the overall cohort but did significantly reduce the risk in the subset of women with increased cardiovascular risk, requiring confirmation in trials with evaluation of cardiovascular outcomes as the primary objective. Expand
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
TLDR
It is concluded that raloxifene continues to reduce the risk of breast cancer in women with osteoporosis after 4 years of treatment, through prevention of new cancers or suppression of subclinical tumors, or both. Expand
Meta-Analyses of Therapies for Postmenopausal Osteoporosis
TLDR
The Osteoporosis Methodology Group’s findings and recommendations will help improve the quality of clinical trials and improve the prognosis for patients with suspected oesophageal cancer. Expand
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
TLDR
In postmenopausal women with osteoporosis, raloxifene increases bone mineral density in the spine and femoral neck and reduces risk of vertebral fracture and was associated with a lower incidence of breast cancer. Expand